Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms

Anticancer drugs continue to cause significant reductions in left ventricular ejection fraction resulting in congestive heart failure. The best-known cardiotoxic agents are anthracyclines such as doxorubicin. For several decades, cardiotoxicity was almost exclusively associated with anthracyclines, for which cumulative dose-related cardiac damage was the use-limiting step. Human epidermal growth factor receptor 2 (HER2; ErbB2) has been identified as an important target for breast cancer. Trastuzumab (TRZ), a humanized anti-HER2 monoclonal antibody, is currently recommended as first-line treatment for patients with metastatic HER2+ tumours. The use of TRZ may be limited by the development of drug intolerance, such as cardiac dysfunction. Cardiotoxicity has been attributed to free-iron-based, radical-induced oxidative stress. Many approaches have been promoted to minimize these serious side effects, but they are still clinically problematic. A new approach to personalized medicine for cancer that involves molecular screening for clinically relevant genomic alterations and genotype-targeted treatments is emerging.

Luc Rochette, Charles Guenancia, Aurélie Gudjoncik, Olivier Hachet, Marianne Zeller, et al.. Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends in Pharmacological Sciences, 2015, 36 (6), pp.326-348. ⟨10.1016/j.tips.2015.03.005⟩ (lien externe). ⟨hal-03434138⟩ (lien externe)